Medicine Matters rheumatology editorial board member Philip Mease summarizes research on new therapeutic agents for psoriatic arthritis presented at the meeting. This activity is financially supported by Novartis Pharma AG.

The second PsA study, by Philip Mease (Swedish Medical Center and University of Washington, Seattle, USA) and colleagues, found sustained improvements in a range of PROs, including measures of pain, fatigue, and physical function, with bimekizumab treatment in the OLE.

Philip Mease, from the University of Washington in Seattle, USA, and co-authors explained that deucravacitinib selectively “binds to the regulatory domain of the intracellular kinase TYK2,” thereby “limiting off-target effects observed with other kinase inhibitors.”

Philip Mease (University of Washington, Seattle, USA) reported that, at week 16, the ACR20 response rate was significantly higher among people in the brepocitinib 30 mg and 60 mg groups than in the placebo group, at 66.7% and 74.6%, respectively, versus 43.3%.

Philip Mease (University of Washington, Seattle, USA) and co-investigators note that the separation between the guselkumab groups and the placebo group was apparent from week 8 for both BASDAI and ASDAS scores, and was maintained at week 52.

“Brodalumab is a fully human monoclonal antibody with a unique mechanism of action that binds to the IL-17 receptor subunit A (IL-17RA) with high affinity and, as a consequence, blocks the action of multiple proinflammatory cytokines of the IL-17 family, beyond that of IL-17A alone,” say Philip Mease (Swedish Medical Center, Seattle, Washington, USA) and co-investigators.

Philip Mease describes the findings from the SELECT-PsA-2 trial of upadacitinib in patients with psoriatic arthritis and an inadequate response to biologic DMARDs (6.18).

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).

Philip Mease said that the findings from DISCOVER-2 “are very consistent with what was shown in DISCOVER-1.”

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.

Philip Mease declares the following relationships: Grants/research support: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Consulting or advisory role: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Participation in a company sponsored speaker bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB

Click through to listen to lead investigator Philip Mease discussing the DISCOVER-2 trial results at the 2019 ACR/ARP Annual Meeting The approval of guselkumab for PsA is based on the results of two phase 3 trials, DISCOVER-1 and DISCOVER-2 , which demonstrated significantly greater ACR20 response rates with the IL-23 inhibitor versus placebo among PsA patients who were either biologic-naïve or had received prior treatment with up to two tumor necrosis factor inhibitors. m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

Lead investigator Philip Mease (Swedish Medical Center and University of Washington, Seattle, USA) reported that ACR20 response rates at week 12 were significantly higher among the 211 patients randomly assigned to receive upadacitinib 15 mg/day and the 218 given upadacitinib 30 mg/day compared with the 212 given placebo, at 57% and 64% versus 24%.

News story |  Ixekizumab tops adalimumab in head-to-head PsA trial Researcher comment | LISTEN: Lead investigator Philip Mease reports the results Expert commentary  |  WATCH: Laura Coates gives her perspective on the results

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis (7:15).

News story |  Tildrakizumab shows promise for PsA Researcher comment | LISTEN: Philip Mease outlines the results